However, in a bispecific antibody format, combining CD95 (senescence-specificity) with another senescent tumor-associated antigen like CD276 or CD340 (to enforce tumor-specificity further) might be able to capitalize on the ~ 20-fold CD95 expression increase and re-establishment of apoptosis in senescent HCC cells. This evidence concerns the gene FAS and neoplasm.